This study found that early administration of heparin, particularly in sufficient doses (Heparin Sodium 5000 units/mL, 1 mL per dose, three times daily (TID)) for more than 7 d, was associated with reduced near-term mortality in critically ill patients with pneumonia-induced sepsis.

These findings underscore the potential benefits of anticoagulant therapy in this high-risk patient population.

1,586 adult patients were enrolled with pneumonia-induced sepsis.

After PSM, 1,176 patients remained (588 in the heparin group and 588 in the non-heparin group).

The 45-d survival rate was significantly higher in the heparin-treated group than that in the non-heparin group.

Read More